News Filter
News Articles List
Sarah Cannon
December 08, 2014
Sarah Cannon Research Institute (SCRI) announced today that its investigators have authored 16 clinical trial abstracts accepted for presentation...
Sarah Cannon
December 04, 2014
Presence Reinforces Leadership Position in Blood Cancer Research & Care
Sarah Cannon
June 02, 2014
Sarah Cannon
May 22, 2014
Sarah Cannon
May 22, 2014
NASHVILLE, TN, May 22, 2014 – Sarah Cannon Research Institute (SCRI) announced today that the American Society for Clinical Oncology (ASCO®) ...
Sarah Cannon
February 26, 2014
Presence Reinforces Leadership Position in Transplantation
Integrated partnership expands cancer services in the Rocky Mountain Region
Social Media
Sarah Cannon Cancer Network
Aug 19, 2017 - 10:16am EDT
First-in-class agonist anti-CD27 antibody varlilumab is well tolerated and active in patients with advanced solid tumors. Learn more about this co-stimulatory molecule on T cells from phase 1 study with Dr. Burris. http://bit.ly/2v1bd7E #FightingCancerTogether
Sarah Cannon Cancer Network
Aug 18, 2017 - 10:44am EDT
Clinical Trial Available for Gyn Onc Patients Are you or a loved one facing ovarian or other type of gynecologic cancer? Sarah Cannon and AstraZeneca are now enrolling patients across the US, Canada and the UK in a clinical study for a novel agent plus chemotherapy. In order to be considered, you must: • have had prior treatments for recurrent cancer • have good kidney, liver and heart function • not be pregnant Learn more http://bit.ly/2i6LFEd